Studies comparing the biology of VN-MCCs to VP-MCCs might ultimately determine a minimum set of signalling pathways that must be disrupted — either by mutation or by viral infection — to initiate MCC tumorigenesis. This evidence concerns the gene HYAL2 and viral infectious disease.